Propanc Biopharma shares rise 14.24% after-hours after unveiling PRP proenzyme therapy targeting pancreatic cancer with Phase 1b trial plans in 2026.

Propanc Biopharma (PPCB) surged 14.24% in after-hours trading following the announcement of its lead proenzyme therapy PRP, a novel treatment targeting pancreatic cancer and solid tumors. The therapy, combining trypsinogen and chymotrypsinogen, demonstrated over 85% tumor growth inhibition in preclinical studies and received FDA Orphan Drug Designation in 2017. The company plans a Phase 1b First-In-Human trial in 2026, evaluating PRP in 30–40 patients with advanced solid tumors at Melbourne’s Peter MacCallum Cancer Centre. The move positions Propanc to address a high-unmet-need market, with the global pancreatic cancer treatment market projected to grow from $3.25 billion in 2025 to $10.25 billion by 2034. PRP’s differentiated mechanism—targeting cancer stem cells and altering tumor microenvironments—positions it as a potential alternative to conventional therapies with reduced toxicity, aligning with investor optimism for innovative oncology candidates.